IO Biotech, Inc. Announces USD 75 Million Private Placement Financing

by | Aug 9, 2023

IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $75 million, before deducting offering expenses. The private placement includes participation from new and existing investors.  

Press inquiries should be adressed to:

Claus Andersson, PhD

General Partner